HC Wainwright Lowers Barinthus Biotherapeutics (NASDAQ:BRNS) Price Target to $3.00

Barinthus Biotherapeutics (NASDAQ:BRNS) had its price target lowered by stock analysts at HC Wainwright from $5.00 to $3.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 216.62% from the stock’s previous close.

Barinthus Biotherapeutics Stock Up 0.8 %

Shares of Barinthus Biotherapeutics stock opened at $0.95 on Monday. The firm has a market cap of $38.12 million, a PE ratio of -0.64 and a beta of -0.81. Barinthus Biotherapeutics has a twelve month low of $0.80 and a twelve month high of $4.16. The business has a 50-day moving average price of $1.07 and a 200 day moving average price of $1.24.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.23. The business had revenue of $14.97 million for the quarter. During the same period last year, the firm posted ($0.37) earnings per share. On average, sell-side analysts expect that Barinthus Biotherapeutics will post -1.52 EPS for the current year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.